[Antiplatelet thromboprophylaxis of arterial vascular diseases and organovascular ischemic diseases]
| Autor: | Anna Petrášová, Eva Gavorníková, Andrej Dukát, Lujza Sabolová, Naďa Hučková, Gabriela Gubo, Ľudovít Gašpar, Iveta Gasparova, Peter Gavorník |
|---|---|
| Jazyk: | čeština |
| Rok vydání: | 2017 |
| Předmět: |
Platelet Function Tests
030204 cardiovascular system & hematology Pharmacology 03 medical and health sciences 0302 clinical medicine Internal Medicine medicine Potency Humans Platelet cardiovascular diseases 030212 general & internal medicine Dosing Platelet activation Vascular Diseases Aspirin business.industry Thrombosis medicine.disease Platelet Activation Pharmacodynamics Onset of action Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors circulatory and respiratory physiology medicine.drug |
| Zdroj: | Vnitrni lekarstvi. 63(2) |
| ISSN: | 0042-773X |
| Popis: | Antiplatelet therapy by acetylsalicylic acid (ASA, aspirin) provided pivotal advances in the prevention and treatment of organovascular (angiovascular, cardiovascular, cerebrovascular, extremitovascular, renovascular, genitovascular, mesenteriointestinokolonovascular, bronchopulmovascular, oculovascular, otovascular and other) arterial ischemic diseases. Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects.Key words: arteriothromboprophylaxis - arterial thrombosis - classic antiplatelet drugs - new antiplatelet agents - organovascular arterial diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|